Advertisement

Autoimmune hemolytic anemia in refractory hairy cell leukemia on dabrafenib and trametinib

  • Damond Barrick NgEmail author
  • Gary Schiller
  • Edward Ha
Letter to the Editor

Dear Editor,

Hairy cell leukemia (HCL) is a rare, indolent B cell malignancy characterized by bone marrow infiltration, splenomegaly, pancytopenia, and neoplastic cells morphologically with cytoplasmic “hair-like” projections [1]. Analogous to other B cell disorders, autoimmune diseases have been reported in HCL; however, autoimmune hemolytic anemia (AIHA) has seldom been reported [2, 3].

We report a 74-year-old man with refractory HCL on dabrafenib/trametinib who presented with fatigue, dyspnea, dark red urine, and dizziness exacerbated by hot showers. He was diagnosed with HCL at the age of 53 years and treated with cladribine resulting in a complete response (CR) that lasted 15 years before requiring reinduction. Three years later, the patient was enrolled in a moxetumomab pasudotox trial for refractory HCL, but his bone marrow persistently exhibited disease after six cycles. Sustained partial remission was achieved while on dabrafenib/trametinib trial for 1.5 years prior to...

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Bouroncle BA, Wiseman BK, Doan CA (1958) Leukemic reticuloendotheliosis. Blood. 13(7):609–630Google Scholar
  2. 2.
    Dasanu CA, Van den bergh M, Pepito D, Alvarez argote J (2015) Autoimmune disorders in patients with hairy cell leukemia: are they more common than previously thought? Curr Med Res Opin 31(1):17–23CrossRefGoogle Scholar
  3. 3.
    Anderson LA, Engels EA (2010) Autoimmune conditions and hairy cell leukemia: an exploratory case-control study. J Hematol Oncol 3:35CrossRefGoogle Scholar
  4. 4.
    Tallman MS (2011) Implications of minimal residual disease in hairy cell leukemia after cladribine using immunohistochemistry and immunophenotyping. Leuk Lymphoma 52(suppl2):65–68CrossRefGoogle Scholar
  5. 5.
    Mhawech-Fauceglia P, Oberholzer M, Aschenafi S, Baur A, Kurrer M, Von Rohr A et al (2006) Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a long-term follow-up in patients treated with cladribine for hairy cell leukemia. Arch Pathol Lab Med 130:374–377Google Scholar
  6. 6.
    Yang L, Rau R, Goodell MA (2015) DNMT3A in haematological malignancies. Nat Rev Cancer 15(3):152–165CrossRefGoogle Scholar
  7. 7.
    Grob JJ, Flaherty KT, Long GV, Nathan PD, Schadendorf D, Ribas A, Robert C, Lane SR, Mak C, Legenne P, Davies MA (2016) Pooled analysis of safety with extended 3-year follow-up across combination dabrafenib and trametinib phase 3 trials. J Clin Oncol 34(15_suppl):9534–9534.  https://doi.org/10.1200/JCO.2016.34.15_suppl.9534 CrossRefGoogle Scholar
  8. 8.
    Viens D, St-hilaire E, Beauregard P, Dufresne J, Knecht H (2008) Successful treatment of warm antibody (IgG/C3 positive) autoimmune hemolytic anemia in hairy-cell leukemia with 2-CdA in the elderly. Leuk Lymphoma 49(7):1424–1426CrossRefGoogle Scholar
  9. 9.
    Cesana C, Brando B, Boiani E, Chiodo F, Cairoli R, Intropido L, Morra E (2002) Effective treatment of autoimmune hemolytic anemia and hairy cell leukemia with interferon-alpha. Eur J Haematol 68(2):120–121CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.David Geffen School of MedicineUniversity of California, Los AngelesLos AngelesUSA
  2. 2.Division of Hematology/Oncology, Department of MedicineUniversity of California, Los AngelesLos AngelesUSA
  3. 3.Department of MedicineUniversity of California, Los AngelesLos AngelesUSA

Personalised recommendations